Patent extensions
Executive Summary
Hearing on patent life of so-called "pipeline" drugs and other Waxman/Hatch related topics has been cancelled by the House Judiciary/Courts & Intellectual Property Subcommittee after the Pharmaceutical Research & Manufacturers of America decided to concentrate its lobbying efforts on Medicare rather than on patent reform. However, generic trade groups remain concerned that Schering-Plough will seek passage of a measure to extend the patent for Claritin as part of a supplemental appropriations bill
|
Hearing on patent life of so-called "pipeline" drugs and other Waxman/Hatch related topics has been cancelled by the House Judiciary/Courts & Intellectual Property Subcommittee after the Pharmaceutical Research & Manufacturers of America decided to concentrate its lobbying efforts on Medicare rather than on patent reform. However, generic trade groups remain concerned that Schering-Plough will seek passage of a measure to extend the patent for Claritin as part of a supplemental appropriations bill. |